arrow
M

Maria I. Carlo

Memorial Sloan Kettering Cancer Center
H指数:41
被引数:7,708

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Ovarian sex cord-stromal tumors are part of the BAP1-tumor predisposition syndrome: evidence from human carriers and mouse models

卵巢性索间质肿瘤是BAP1-肿瘤倾向综合征的一部分:来自人类携带者和小鼠模型的证据

2026-10-210
OAAI
24 A Phase 1b/2 Study of Abemaciclib Plus Cabozantinib in Immune Checkpoint Blockade-Pretreated Metastatic Clear Cell Renal Cell Carcinoma and Translocation-Associated Renal Cell Carcinoma (NCT06835972)

24 一项关于阿贝西利联合卡博替尼在免疫检查点阻断预处理后的转移性透明细胞肾细胞癌和转位相关肾细胞癌中的1b/2期研究(NCT06835972)

2026-09-020
OAAI
78 Dietary Fructose Intake and Tumoral Fructose-Metabolism Gene Expression in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Blockade

78 饮食果糖摄入与接受免疫检查点阻断治疗转移性肾细胞癌的肿瘤果糖代谢基因表达

2026-09-020
OAAI
Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers

高级泌尿肿瘤共识会议(AUC3)2025:肾细胞癌和尿路肿瘤管理的专家共识

2025-12-130
OAAI
Subclinical Telomere Biology Disorder in Cancer Patients Heterozygous for the RTEL1 R1264H Founder Variant

癌症患者中杂合子RTEL1 R1264H始祖变异的亚临床端粒生物学障碍

2025-12-010
PRE
MLH1 Mismatch Repair Deficiency Predicts Exceptional Response to Immune Checkpoint Inhibition in Clear-cell Renal Cell Carcinoma

MLH1错配修复缺陷预测透明细胞肾细胞癌对免疫检查点抑制的显著反应

2025-11-040
PRE
Defining the Histopathological, Clinical, and Genetic Characteristics of Familial BAP1-associated Renal Cell Carcinoma

定义家族性BAP1相关性肾细胞癌的病理组织学、临床和遗传特征

2025-09-080
PRE
Developing biomarkers and methods of risk stratification: Consensus statements from the International Kidney Cancer Symposium North America 2024 Think Tank

开发生物标志物和风险分层方法:国际肾癌研讨会北美2024年思辨研讨会的共识声明

2025-09-010
PRE
Germline landscape of high grade serous ovarian cancer across age groups: Is age just a number?

高级别浆液性卵巢癌在年龄组间的种系景观:年龄仅仅是一个数字吗?

2025-08-130
PRE
A Phase 1b/2 Study of Talazoparib and Axitinib in Patients with Advanced Clear-cell Renal Cell Carcinoma

一项关于talazoparib和axitinib治疗晚期透明细胞肾细胞癌的1b/2期研究

2025-03-290
PRE
Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase II Trial (vol 86, pg 90, 2024)

卡博替尼联合纳武利尤单抗治疗非透明细胞肾细胞癌:一项II期试验的更新结果(卷86,页90,2024)

2025-01-010
PRE